Evidence-informed pharmacology monograph updated 10 November 2026. Educational content, not a substitute for patient-specific assessment, institutional protocols or current product labeling.
Overview and correct indication
Nimodipine is a lipophilic dihydropyridine L-type calcium channel blocker with an established role in improving neurologic outcomes following aneurysmal subarachnoid hemorrhage (aSAH). Although its vascular effects may reduce calcium-dependent vasoconstriction, the clinical benefit cannot be explained solely by reversal of large-vessel vasospasm. It is not a routine indication for all ischemic strokes, nonaneurysmal hemorrhage or systemic hypertension [1–3].
Mechanism and pharmacodynamics
Nimodipine blocks L-type calcium influx in vascular smooth muscle and can dilate cerebral and systemic arteries. Aneurysmal SAH can lead to delayed cerebral ischemia through mechanisms including vasospasm, microthrombosis, inflammation and cortical spreading depolarization; nimodipine improves functional outcomes in trials despite uncertain linkage to radiographic vessel dilation. Excess systemic hypotension can reduce brain perfusion, so careful BP assessment is essential [1,2].
Administration: life-threatening route warning
Oral nimodipine capsules and oral solutions must NEVER be injected intravenously. Parenteral administration of oral preparations has caused fatal cardiovascular collapse. US labeling specifies oral, nasogastric or gastric-tube administration only. The labeled adult schedule for many US oral products is 60 mg every four hours for 21 days, started within 96 hours of onset of aSAH; tube administration must use an enteral syringe and product-specific directions. Cirrhosis can require dose reduction. This is educational label information, not a patient order [2,3].
Pharmacokinetics and interactions
Nimodipine has extensive first-pass metabolism mediated substantially by CYP3A4; peak concentrations and exposure are influenced by food, liver function and drug interactions. Strong CYP3A4 inhibitors can lead to dangerous hypotension, while strong inducers may diminish exposure and effectiveness. Grapefruit can increase exposure. Monitor drug interactions, BP and functional neurological status throughout the course [2].
Guideline-based clinical use
The 2023 AHA/ASA aSAH guideline recommends early enteral nimodipine to prevent delayed cerebral ischemia and improve functional outcomes. Continuity of treatment is important, with clinicians responding to hypotension by individualized adjustments rather than automatic prolonged interruption. Surgical/endovascular securing of the aneurysm, euvolemia, monitoring for delayed ischemia and broader neurocritical care remain crucial [1].
Adverse effects and special populations
Hypotension, headache, nausea and dizziness may occur. Severe hepatic impairment increases exposure and requires caution/dose adjustment. Nimodipine should not be administered through IV or other parenteral routes with oral products, and must not be confused with injectable nicardipine, another dihydropyridine with different indications [2,3].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 guideline for management of patients with aneurysmal subarachnoid hemorrhage. Stroke. 2023;54:e314–e370. doi:10.1161/STR.0000000000000436. Available from: https://professional.heart.org/en/science-news/2023-guideline-for-the-management-of-patients-with-aneurysmal-subarachnoid-hemorrhage/top-things-to-know
- DailyMed. NYMALIZE (nimodipine) oral solution: prescribing information, revised August 2024. Available from: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e660fa26-b5c4-4d6d-8887-9e22b6666a10
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.